AVITA Medical Q4 2022 Earnings Report $13.79 +0.14 (+1.03%) As of 01:56 PM Eastern Earnings HistoryForecast AVITA Medical EPS ResultsActual EPS-$0.21Consensus EPS -$0.32Beat/MissBeat by +$0.11One Year Ago EPSN/AAVITA Medical Revenue ResultsActual Revenue$9.46 millionExpected Revenue$8.67 millionBeat/MissBeat by +$790.00 thousandYoY Revenue GrowthN/AAVITA Medical Announcement DetailsQuarterQ4 2022Date2/23/2023TimeN/AConference Call ResourcesPress ReleaseRCEL Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by 3 golden rules for dividends (Ad)If you have any interest in building a great dividend portfolio, you will want to watch legend, Jack Carter’s briefing asap: The 3 Golden Rules for a Powerhouse Dividend Portfolio During this class, Jack walks you through all three of his “golden rules” and how they work. He even shares specific tickers that meet his criteria which you could consider adding to your portfolio today! And he explains each of his golden rules in detail.Just tap here to join the presentation. AVITA Medical Earnings HeadlinesAVITA Medical Just Tripled Its TAM In The Burn MarketJanuary 2, 2025 | seekingalpha.comCantor Fitzgerald bullish on Avita Medical after FDA approval for RECELL GO MiniDecember 25, 2024 | finance.yahoo.comCombine the QQQ, IWM and SPY in one tradeIf you’ve been investing in the major indexes for the last 20 years, you may need a new strategy. Because the Dow Jones has returned just 349%... The Russell 2000 has returned just 397%... And the S&P 500 has returned just 450%. And although I can’t guarantee results or against losses… I want to tell you about my “2-Click Trade” that has encapsulated more than the return of ALL THREE OF THOSE INDEXES COMBINED… Plus, it targets multiple overnight payouts in a month with 84.3% accuracy! While I cannot promise future returns or against losses…January 7, 2025 | Diversified Trading Institute (Ad)Avita Medical initiated with a Buy at D. Boral CapitalDecember 25, 2024 | markets.businessinsider.comLake Street Reaffirms Their Buy Rating on Avita Medical (RCEL)December 25, 2024 | markets.businessinsider.comD. Boral Capital Initiates Coverage of AVITA Medical (RCEL) with Buy RecommendationDecember 25, 2024 | msn.comSee More AVITA Medical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like AVITA Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AVITA Medical and other key companies, straight to your email. Email Address About AVITA MedicalAVITA Medical (NASDAQ:RCEL), together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.View AVITA Medical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles S&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Upcoming Earnings Schlumberger (1/17/2025)Procter & Gamble (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
